If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...